Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity
Immune checkpoint inhibitors (ICI) boost the endogenous anticancer immunity, evoking long-lasting anticancer responses in a subset of patients with solid tumors. Simultaneously, ICI are also associated with serious toxicities, impacting treatment duration and the quality of life. The proposed proces...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/5/e011009.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849728702215094272 |
|---|---|
| author | Rachel S van der Post I Jolanda M de Vries Willemijn A van Dop Erik Aarntzen Sandra Heskamp Hans J P M Koenen Harm Westdorp Manfred Kneilling Eva Peeters Evelien A J van Genugten Carla van Herpen |
| author_facet | Rachel S van der Post I Jolanda M de Vries Willemijn A van Dop Erik Aarntzen Sandra Heskamp Hans J P M Koenen Harm Westdorp Manfred Kneilling Eva Peeters Evelien A J van Genugten Carla van Herpen |
| author_sort | Rachel S van der Post |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICI) boost the endogenous anticancer immunity, evoking long-lasting anticancer responses in a subset of patients with solid tumors. Simultaneously, ICI are also associated with serious toxicities, impacting treatment duration and the quality of life. The proposed processes underlying ICI-related toxicity include T-cell activation and recruitment to non-tumor tissues, involvement of other immune cells and fibroblasts and the host’ microbiome composition. However, the exact mechanisms of these processes remain incompletely understood, hindering clinicians’ ability to predict and identify ICI-related toxicity in the early stages of treatment. Molecular imaging may play a role as a non-invasive biomarker, providing a tool to study ICI-related toxicity. This review discusses the applications of molecular imaging to answer questions regarding the mechanisms, detection, and prediction of ICI-related toxicity. Potential targets and the current state of development of suitable imaging techniques are discussed. |
| format | Article |
| id | doaj-art-531c405b0ec74bcd989203ddca687bc1 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-531c405b0ec74bcd989203ddca687bc12025-08-20T03:09:28ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-05-0113510.1136/jitc-2024-011009Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicityRachel S van der Post0I Jolanda M de Vries1Willemijn A van Dop2Erik Aarntzen3Sandra Heskamp4Hans J P M Koenen5Harm Westdorp6Manfred Kneilling7Eva Peeters8Evelien A J van Genugten9Carla van Herpen10Department of Pathology, Radboud University Medical Center, Nijmegen, Gelderland, The NetherlandsMedical BioSciences, Radboud University Medical Center, Nijmegen, The NetherlandsDepartment of Gastroenterology, Radboud University Medical Center, Nijmegen, Gelderland, The NetherlandsMedical Imaging, Radboud University Medical Center, Nijmegen, The NetherlandsMedical Imaging, Radboud University Medical Center, Nijmegen, The NetherlandsLaboratory of Medical Immunology, Radboud University Medical Center, Nijmegen, Gelderland, The NetherlandsMedical Oncology, Radboud University Medical Center, Nijmegen, The NetherlandsDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, University of Tübingen, Tubingen, Baden-Württemberg, GermanyMedical Imaging, Radboud University Medical Center, Nijmegen, The NetherlandsMedical Imaging, Radboud University Medical Center, Nijmegen, The NetherlandsMedical Oncology, Radboud University Medical Center, Nijmegen, The NetherlandsImmune checkpoint inhibitors (ICI) boost the endogenous anticancer immunity, evoking long-lasting anticancer responses in a subset of patients with solid tumors. Simultaneously, ICI are also associated with serious toxicities, impacting treatment duration and the quality of life. The proposed processes underlying ICI-related toxicity include T-cell activation and recruitment to non-tumor tissues, involvement of other immune cells and fibroblasts and the host’ microbiome composition. However, the exact mechanisms of these processes remain incompletely understood, hindering clinicians’ ability to predict and identify ICI-related toxicity in the early stages of treatment. Molecular imaging may play a role as a non-invasive biomarker, providing a tool to study ICI-related toxicity. This review discusses the applications of molecular imaging to answer questions regarding the mechanisms, detection, and prediction of ICI-related toxicity. Potential targets and the current state of development of suitable imaging techniques are discussed.https://jitc.bmj.com/content/13/5/e011009.full |
| spellingShingle | Rachel S van der Post I Jolanda M de Vries Willemijn A van Dop Erik Aarntzen Sandra Heskamp Hans J P M Koenen Harm Westdorp Manfred Kneilling Eva Peeters Evelien A J van Genugten Carla van Herpen Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity Journal for ImmunoTherapy of Cancer |
| title | Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity |
| title_full | Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity |
| title_fullStr | Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity |
| title_full_unstemmed | Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity |
| title_short | Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity |
| title_sort | exploring molecular imaging to investigate immune checkpoint inhibitor related toxicity |
| url | https://jitc.bmj.com/content/13/5/e011009.full |
| work_keys_str_mv | AT rachelsvanderpost exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT ijolandamdevries exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT willemijnavandop exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT erikaarntzen exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT sandraheskamp exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT hansjpmkoenen exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT harmwestdorp exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT manfredkneilling exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT evapeeters exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT evelienajvangenugten exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity AT carlavanherpen exploringmolecularimagingtoinvestigateimmunecheckpointinhibitorrelatedtoxicity |